At this point it seems like Resverlogix will be bought/merged/lisenced based on the out come of the BETOnMACE findings which limited Apabetalone to those with type 2 diabetes and low HDL cholesterol....  is there any future hope for those outside the BETOnMace target???  Did they limit the target because they had the best chance of succeeding and didn't have the $$$$$ To expand from the 2425 patient enrolment?